



NEW PERSPECTIVES IN DIABETES

NEW TARGETS, NEW THERAPIES, AND A
NEW APPROACH TO PATIENT MANAGEMENT

Program Title: The Emerging Role of SGLT Inhibitors in Individualized Treatment of T2DM

Activity Faculty

George L. Bakris, MD
Professor of Medicine
Director, ASH Comprehensive Hypertension Center
The University of Chicago
Chicago, Illinois

45 Minutes: The Emerging Role of SGLT Inhibitors in Individualized Treatment of T2DM

15 minutes: Questions and Answers

Content Faculty

John E. Gerich, MD (Chair)

University of Rochester School of Medicine

George L. Bakris, MD

The University of Chicago

Vivian A. Fonseca, MD, FRCP

Tulane University School of Medicine

Robert R. Henry, MD

University of California, San Diego
Veterans Affairs Healthcare System

Lawrence A. Leiter, MD, FRCP(C), FACP

University of Toronto

Sponsored by



The France Foundation

Target Audience

This activity is intended for primary care physicians and other health care professionals who manage patients with type 2 diabetes.

Educational Activity Learning Objectives

Upon completion of this course, the participants should be able to:

- Define individual T2DM and cardiovascular disease goals
- Formulate a patient management strategy that targets the “ABCs”: A1C, Blood Pressure, and Cholesterol
- Explain the rationale for targeting renal glucose transport, and interpret related clinical data and the potential role
- Distinguish the unique differences between new SGLT2 inhibitors and discuss the clinical implications of these differences on appropriate patient selection

Statement of Need

This activity is designed to improve knowledge, competency, and practice improvements in the diagnosis, management, and treatment of patients with type 2 diabetes mellitus (T2DM).

Disclosures

It is the policy of The France Foundation to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All faculty, activity planners, content reviewers, and staff participating in this activity will disclose to the participants any significant financial interest or other relationship with manufacturer(s) of any commercial product(s)/device(s) and/or provider(s) of commercial services included in this educational activity. The intent of this disclosure is not to prevent a person with a relevant financial or other relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. The France Foundation has identified and resolved any and all conflicts of interest prior to the release of this activity.

Activity Staff Disclosures

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Faculty Disclosures—Content Creators

The following faculty have indicated they have relationships with industry to disclose relative to the content of this CME activity:

- **John E. Gerich, MD**, has served as a consultant for and/or received honoraria from Janssen, Boehringer Ingelheim, Eli Lilly, Bristol-Myers Squibb, AstraZeneca, Sanofi, and Merck
- **George L. Bakris, MD**, has received grant and research support from Takeda and has served as a consultant for Janssen, Medtronic, Relypsa, Takeda, Daiichi-Sankyo, Boehringer Ingelheim, and Bristol-Myers Squibb
- **Vivian A. Fonseca, MD, FRCP**, has received research support from Novo-Nordisk, Sanofi-Aventis, Eli Lilly, Abbott, Pan American Laboratories, Reata, and Endo Barrier and has served as a consultant and speaker for GlaxoSmithKline, Takeda, Novo-Nordisk, Sanofi Aventis, Eli Lilly, Daiichi-Sankyo, PamLab, AstraZeneca, Abbott, Bristol-Myers Squibb, and Boehringer Ingelheim
- **Robert R. Henry, MD**, has received grant and research support from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Sanofi-Aventis, and has served as a consultant or on an advisory board for Alere, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, ClinMet, Daiichi Sankyo, Eisai, Elcelyx, Gilead, Hitachi, Intarcia, Isis, Johnson & Johnson/Janssen, Eli Lilly, Merck, Novo Nordisk, Roche/Genentech, Sanofi Aventis, and Vivus, Inc
- **Lawrence Leiter, MD, FRCP(C), FACP**, has received grants, research support, and has served as consultants for Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novo Nordisk, Roche, Sanofi, Servier, and Takeda. Dr. Leiter has received honoraria from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Merck, Novo Nordisk, Sanofi, and Takeda

Faculty Disclosures—Faculty Activity

The following faculty has indicated he has relationships with industry to disclose relative to the content of this CME activity:

- **George L. Bakris, MD**, has received grant and research support from Takeda and has served as a consultant for Janssen, Medtronic, Relypsa, Takeda, Daiichi-Sankyo, Boehringer Ingelheim, and Bristol-Myers Squibb

Unapproved Use Disclosure

The France Foundation requires CME faculty (speakers) to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

Commercial Support Acknowledgment

This activity is supported by an educational grant from Bristol-Myers Squibb and AstraZeneca.

Disclaimer

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, Bristol-Myers Squibb, and AstraZeneca assume no liability for the information herein.